✨ Free AI Report
Numerion Labs: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Numerion Labs
Company Research

Numerion Labs: Business Overview, Financials & Competitive Analysis

Numerion Labs specializes in AI-based drug discovery services, developing small-molecule drug candidates using atomnet technology, which employs deep learning for structure-based drug design. The company rebranded fro...

Analyst-debate audio for Numerion Labs

AskCyborg analysts argue the bull and bear cases for Numerion Labs across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Validated AI-first drug discovery platform with strong pharma partnerships and breakthrough APEX technology enabling...

Read the full analyst-debate transcript →
Industry Drug Discovery Services
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Numerion Labs Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Numerion Labs Overview

Pro stress-test →

Numerion Labs specializes in AI-based drug discovery services, developing small-molecule drug candidates using atomnet technology, which employs deep learning for structure-based drug design. The company rebranded from Atomwise in October 2025, with a strategic focus on ultra-fast virtual screening (APEX) and immune/inflammatory disease programs.

Strategic Profile

Pro stress-test →

The company collaborates with over 250 partners, including pharmaceutical and biotechnology companies, to address various disease targets. Numerion Labs developed APEX to address the inability to comprehensively search chemical space at scale, pairing deep learning surrogates with GPU-accelerated enumeration to virtually evaluate billions of potential starting points in seconds.

Competitive Landscape

Pro stress-test →

BenevolentAI concentrates on upstream target and indication discovery using knowledge-graph-driven biology, while Insilico spans an end-to-end generative AI pipeline with autonomous lab and clinical assets, whereas Numerion specializes in structure-based virtual screening for small-molecule hits. Other noted competitors include X-37, Exscientia, Inovio Pharmaceuticals, Verge Analytics, and Enterprise Therapeutics.

Industry Context

Numerion Labs operates in Drug Discovery Services.

Key facts

Founded: 2012 · Headquarters: San Francisco, US · Employees: 67 · Revenue: N/A · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Numerion Labs.

  • AtomNet platform evaluation in 318-target virtual screening study across 250+ academic labs reported success rates of 74-75% and hit rates of 5-6% even without prior actives.
  • APEX technology enables virtual evaluation of billions of molecules in seconds, ensuring promising compounds are not overlooked in comprehensive chemical space exploration.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2025Published breakthrough APEX research with NVIDIA on ultra-fast screening of billions of virtual molecules in seconds, advancing GPU-accelerated chemical space enumeration
  • October 2025Rebranded from Atomwise to Numerion Labs, consolidating focus on ultra-fast virtual screening and immune/inflammatory disease programs
  • +1 moreTrack every material event for Numerion Labs as it happens. Explore monitoring →
Get alerted when Numerion Labs has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BenevolentAIAI-driven target and indication discovery using knowledge-graph biology→Insilico MedicineEnd-to-end generative AI drug discovery pipeline with autonomous lab→ExscientiaAI-powered drug discovery platform with multiple clinical programs→X-37AI drug discovery platform→

Compare Numerion Labs with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Numerion Labs operates in Drug Discovery Services. See how the rest of the sector scores on the Cyborg framework.

Browse Drug Discovery Services research →
NEW · MCP server

Ask your AI assistant about Numerion Labs

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Numerion Labs and its top competitor on Cyborg Score”
“What did Numerion Labs do this quarter?”
“Is Numerion Labs a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Numerion Labs do?+
Numerion Labs specializes in AI-based drug discovery services, developing small-molecule drug candidates using atomnet technology, which employs deep learning for structure-based drug design. The company rebranded fro...
What is Numerion Labs's Cyborg Score?+
Numerion Labs has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Numerion Labs's main competitors?+
Named competitors include BenevolentAI, Insilico Medicine, Exscientia, X-37. The full competitive landscape is in the AskCyborg report.
How can I get the full Numerion Labs research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Numerion Labs research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Numerion Labs over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.